Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246012 | 1.00 | NAAA (0.60) | NAAACA12CA1CA2CA9 | |
| SCHEMBL391505 | 1.00 | NAAA (0.60) | NAAACA12CA1CA2CA9 | |
| SCHEMBL26143 | 1.00 | NAAA (0.60) | NAAACA12CA1CA2CA9 | |
| SCHEMBL931393 | 1.00 | NAAA (0.60) | NAAACA12CA1CA2CA9 | |
| SCHEMBL9720411 | 0.89 | ALDH1A1 (0.52) | NAAACA12CA1CA2CA9 | |
| SCHEMBL2701154 | 0.87 | LPAR2 (0.53) | NAAAFAAH | |
| SCHEMBL6185868 | 0.84 | ALDH1A1 (0.48) | NAAACA12CA1CA2CA9 | |
| SCHEMBL27579477 | 0.82 | NAAA (0.52) | NAAACA12CA1CA2CA9 | |
| SCHEMBL8448333 | 0.77 | NAAA (0.58) | NAAACA12CA1CA2CA9 | |
| SCHEMBL375009 | 0.77 | NAAA (0.58) | NAAACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123812-A1 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | SHATTUCK LABS, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| EP-4370135-A2 | SINGLE CHAIN VARIABLE FRAGMENT (SCFV) MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | Generation Bio Co. (US) | 2024-05-22 | — | — | EP | claimed |
| WO-2024097875-A1 | FUSION PROTEINS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS | SHATTUCK LABS, INC. (US) | 2024-05-10 | — | — | WO | claimed |
| EP-4351533-A1 | APOE AND APOB MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | Generation Bio Co. (US) | 2024-04-17 | — | — | EP | claimed |
| EP-4334455-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| EP-4333898-A2 | PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| WO-2023239756-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | GENERATION BIO CO. (US) | 2023-12-14 | — | — | WO | claimed |
| WO-2023077156-A1 | MODIFIED MRNA THERAPEUTICS | SHATTUCK LABS, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| WO-2023287861-A2 | SINGLE CHAIN VARIABLE FRAGMENT (SCFV) MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | GENERATION BIO CO. (US) | 2023-01-19 | — | — | WO | claimed |
| WO-2022261101-A1 | APOE AND APOB MODIFIED LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | GENERATION BIO CO. (US) | 2022-12-15 | — | — | WO | claimed |
| EP-2405921-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN C-III EXPRESSION | Protiva Biotherapeutics Inc. (CA) | 2012-01-18 | — | — | EP | claimed |
| WO-2012000104-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-01-05 | — | — | WO | claimed |
| JP-4796062-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| WO-2011038160-A2 | COMPOSITIONS AND METHODS FOR SILENCING GENES EXPRESSED IN CANCER | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-31 | — | — | WO | claimed |
| WO-2011011447-A1 | COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-27 | — | — | WO | claimed |
| WO-2010105372-A1 | COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS C VIRUS EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-09-23 | — | — | WO | claimed |
| WO-2010083615-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN C-III EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-07-29 | — | — | WO | claimed |
| EP-1766035-A1 | LIPID ENCAPSULATED INTERFERING RNA | Protiva Biotherapeutics Inc. (CA) | 2007-03-28 | — | — | EP | claimed |
| WO-2006007712-A1 | METHODS COMPRISING POLYETHYLENE GLYCOL-LIPID CONJUGATES FOR DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-01-26 | — | — | WO | claimed |
| WO-2005121348-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-12-22 | — | — | WO | claimed |